503b bulk exclusion
Why FDA Exclusion Kills Semaglutide Clinics
Within three weeks of the FDA’s 503B bulk exclusion, clinics have lost their cheapest source of semaglutide, causing treatment delays and rising costs. By removing semaglutide, tirzepatide and liraglutide from the bulk list, the agency forces compounding pharmacies to restart certification processes, leaving patients scrambling for a steady supply.